Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

uch statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and de
'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, Ltd. ... an agreement with Novella Clinical (Novella), to ... patients with newly diagnosed glioblastoma. Novella is a full-service, ... to small to mid-sized oncology companies. The ICT-107 phase ... the US, Europe and ...
(Date:7/3/2015)... , July 3, 2015 ... voivat hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Open Innovation in Science" -jatkokoulutusohjelmaan ... Boltzmann Gesellschaftin (LBG) tekemän, kansainvälisiä ... mukaan terveystieteiden kaksi suurinta haastetta ...
(Date:7/3/2015)... , July 3, 2015 ... till 22 september 2015 på  http://www.openinnovationinscience.at ... Innovation in Science" som hålls i ... en färsk undersökning med internationella forskare och ... (LBG) är hälsovetenskapens två största utmaningar bristen ...
(Date:7/3/2015)... WIEN , July 3, 2015 /PRNewswire/ ... indtil den 22. september 2015 på  http://www.openinnovationinscience.at ... in Science", der finder sted i ... en nylig undersøgelse af internationale forskere og ... er de to største udfordringer for sundhedsvidenskaben ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
... (NYSE Amex: PTN ) will announce its fourth ... 2011 before the open of the U.S. financial markets. ... audio webcast hosted by its executive management team on September ... operations in greater detail and an update on corporate developments.Schedule ...
... University of Toronto (U of T), the King Abdullah University ... State) have created the most efficient solar cell ever made ... the latest issue of Nature Materials. Quantum dots are ... energy source. Because of their small scale, the dots can ...
... TORONTO, Sept. 16, 2011 Generex Biotechnology Corporation ... Dr. Nicola Napolii, from University Campus Bio-Medico in ... clinical data on Generex Oral-lyn™ buccal insulin spray ... for the Study of Diabetes (EASD) annual meeting ...
Cached Biology Technology:U of T-led research improves performance of next-generation solar cell technology 2U of T-led research improves performance of next-generation solar cell technology 3Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 2Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 3Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 4
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... nearby mosquito is the sound of love, scientists have known ... males and females flap their wings and change their tune ... have discovered that male and female mosquitoes (Aedes aegypti), which ... acoustically with each other when the two are within earshot ...
... evolutionary history of diatoms -- abundant oceanic plankton that remove ... year -- needs to be rewritten, according to a new ... in species numbers, diatoms abruptly declined about 33 million years ... The study is published in the Jan. 8 issue of ...
... available in German . , The ... proton. If a neutron is added, the hydrogen becomes ... of hydrogen atoms are chemically identical. However, there can ... that contain deuterium in place of hydrogen, is toxic ...
Cached Biology News:Mosquitoes create harmonic love song before mating, study finds 2Decline of carbon-dioxide-gobbling plankton coincided with ancient global cooling 2Heavy pyridine crystallizes differently 2
... and clarification reagent; Ideal for clarifying ... antibodies, proteins, nucleic acids, & proteoglycans; ... and improves downstream processing; Utilizes a ... adsorbent supplied as a suspension in ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
... Tecans open platform for clinical diagnostic applications, ... performance in the clinical diagnostic and blood ... barcode reading and sample traceability as standard ... complies with the IVD-Directive* established in the ...
... StabilZyme HRP Conjugate Stabilizer is an ... protein and other non-toxic stabilizing chemicals in ... 6.2 6.7. This product contains ... and 20 ppm Proclin 300 (Rohm and ...
Biology Products: